The Global Summit

Empowering Humanity

"Greater than the Sum of its Parts"   On November 16-18, 2008, vision stewards, thought leaders and technologists united to set the collective vision, subject matter, strategy, criteria and policy making foundation for The Global Summit (TGS) 2010 and beyond.  Proposed dates for TGS 2010 are Nov. 7-11 (including welcome receptions, 3 day conference, and Clos ...learn more

GROUP DETAILS

Created: Nov 18, 2008

Updated: Nov 17, 2009

Membership: Open

Semi-Private

 
Created: Apr 12, 2007
Updated: Apr 12, 2007
Viewed: 91 times
Page Status: active
  •  
Not Yet Rated

Biotech Patents: Equivalency and Exclusions Under European and U.S. Patent Law

Resource Info   Edit

Type: Book
 
Website: http://www.amazon.com/Biotech-...
 
Author: Li Westerlund
 
Publisher: Springer
 
Date published: Fri, Jun 14, 2002
 
Country: United States
 
Scale of activity: 1
 

Network [Add] · [List] · [Visualize]

Connected with 0 organizations
Connected with 0 people
Connected with 0 resources
Connected with 0 solutions
Connected with 0 jobs
Connected with 0 events
Connected with 0 wikipages

 

Areas of Focus  [Edit]

About  [Edit]

There is no denying that biotechnological inventions in some ways have challenged the legal system of providing market exclusivity through patents. First of all, their patentability has been questioned. Furthermore, the scope of protection conferred to these inventions is obscured because of the difficulty of applying legal concepts to complex biological phenomena. It is a recurrent question whether the legal solutions embedded in the patent system in an aggressive market correctly reflect inventors' contribution to the art, thus balancing the conflicting interests in an appropriate manner. When it comes to inventions in the biotechnological field, the requirements that a patent cannot be granted without the invention being disclosed, together with protection against equivalent solutions, raise practical problems, making the clash between technological reality and the legal frameworks evident. This book discusses patent legal issues regarding inventions in the field of biotechnology. The scope of a patent is of central concern, and since biotechnology is very different from other technologies, the requirements for disclosure and infringement are in focus. Eligibility issues are touched upon, although from more of an explanatory perspective, since the law is settled in this respect. The material for the analyses includes the European practices under the EPC, those of the United Kingdom, Germany, and the US. The mandated exclusions from patentability under the European patent laws of categories of plant and animal subject matter and certain biological processes are also analysed. Claim interpretation is the common theme. The challenge has been to present a comprehensive basis for grasping the substantive law for the field of biotechnology. The book examines thoroughly the differences between practices, and the consequences of those differences for the possibility of being granted a patent for an invention, and the infringement doctrines' effects for what might be called a patent's `after-life', i.e. the scope of its protection. As for the exclusions from patentability in Europe, the study reveals an inherent inconsistency in article 53(b) EPC, warranting an adjusted and more patent-legal understanding of the concepts. The principal message emerging in this book is the importance of relying on the policy arguments of uniformity and predictability in order to preserve a fair balance between an inventor and third parties, since in reality much of the controversy in this field turns on proper protection.

Comments

Login to Post a Comment.


Contributors to this Page